Elicio Therapeutics, Inc.
NASDAQ:ELTX · NASDAQ Global Market
+$0.91 today
Vol 4.82M · Avg 0.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-2418.8%
avg -237.2%
ROIC
-201.0%
avg -69.9%
ROA
-153.0%
avg -119.7%
Analysis
ROA is currently the strongest return metric at -153.0% versus its period average of -119.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert T. Connelly | Chief Executive Officer, President & Director | $980,700.00 | — | 66 | $147,200.00 | 0.77% |
Christopher Haqq | Executive Vice President, Head of Research & Development and Chief Medical Officer | $750,000.00 | — | 60 | $57,381.00 | 0.30% |
Preetam Shah | Chief Strategy & Financial Officer and Treasurer | $687,077.00 | — | 53 | $47,900.00 | 0.25% |
Peter DeMuth | Chief Scientific Officer | $648,600.00 | — | 39 | $41,600.00 | 0.22% |
Allen Richard Nissenson FACP | Founder & Independent Director | $52,500.00 | — | 79 | $7,900.00 | 0.04% |
Darrell J. Irvine | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board | — | — | — | — | — |
Esther Welkowsky | Senior Vice President of Clinical Development | — | — | — | — | — |
Megan C. Filoon | General Counsel, Secretary & Compliance Officer | — | — | — | — | — |
Joy Seymour | Vice President & Head of Regulatory Affairs | — | — | — | — | — |
Thian Kheoh | Senior Vice President of Biometrics | — | — | — | — | — |
Marc J. Wolfgang | Chief Technology Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -24.1% | +35.6% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -24.1% over three years. Forward estimates point to Revenue at +35.6% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Actuate Therapeutics Inc
ACTU
$48.33M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages ELTX?
Elicio Therapeutics, Inc. (ELTX) lists 11 active executives. The top listed executive is Allen Richard Nissenson FACP, Founder & Independent Director.
Are ELTX insiders buying or selling?
Recent insider activity shows net buying of $37.26M.
Explore More
Continue the stock analysis
Jump to another research area for this company.